Encapsulation and release of amphotericin B from an ABC triblock fluorous copolymer

Pharmaceutical Research

Volumn 29, Issue 1, 2012, Pages 69-82

  Jee, Jun Pil ^a   McCoy, Aaron ^a   Mecozzi, Sandro ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Amphotericin B; Drug delivery; Fluorous; Polymeric micelle; Stability

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE FLUOROCARBON 10 N [METHOXY(POLYETHYLENE GYLCOL) 2000]; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE FLUOROCARBON 10 N [METHOXY(POLYETHYLENE GYLCOL) 5000]; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GYLCOL) 2000]; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GYLCOL) 5000]; AMPHOTERICIN B; COPOLYMER; MACROGOL; MACROGOL 2000; UNCLASSIFIED DRUG; 1,2 DISTEAROYLPHOSPHATIDYLETHANOLAMINE; 1,2-DISTEAROYLPHOSPHATIDYLETHANOLAMINE; ANTIINFECTIVE AGENT; DRUG CARRIER; FLUOROCARBON; MACROGOL DERIVATIVE; PHOSPHATIDYLETHANOLAMINE;

ARTICLE; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; MICELLIZATION; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; TIMED DRUG RELEASE; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; HALF LIFE TIME; MICELLE; SERUM; SURFACE TENSION;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; DRUG CARRIERS; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUOROCARBONS; HALF-LIFE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICELLES; MOLECULAR STRUCTURE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; SERUM; SURFACE TENSION;

EID: 84860550154     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0511-9     Document Type: Article

References (60)

1. Singh S, Dash AK. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. Crit Rev Ther Drug Carrier Syst. 2009;26(4):333-72.
2. Yoon HJ, Jang WD. Polymeric supramolecular systems for drug delivery. J Mater Chem. 2010;20(2):211-22.
3. Allen TM, Hansen C, Martin F, Redemann C, Yauyoung A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives invivo. Biochim Biophys Acta. 1991;1066(1):29-36.
4. Ashok B, Arleth L, Hjelm RP, Rubinstein I, Onyuksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci. 2004;93(10):2476-87. (Pubitemid 39319431)
5. Gabizon AA, Barenholz Y, BialerM. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid - pharmacokinetic studies in rodents and dogs. Pharm Res. 1993;10(5):703-8. (Pubitemid 23152316)
6. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004;56(9):1273-89. (Pubitemid 38510474)
7. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73(2-3):137-72. (Pubitemid 32544594)
8. Chen H, Kim S, He W, Wang H, Low PS, Park K, et al. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Forster resonance energy transfer imaging. Langmuir. 2008;24(10):5213-7.
9. Savic R, Azzam T, Eisenberg A, Maysinger D. Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: a fluorogenic-based approach. Langmuir. 2006;22(8):3570-8. (Pubitemid 43672524)
10. Xu XY, Zhang XF, Wang XH, Li YX, Jing XB. Comparative study of paclitaxel physically encapsulated in and chemically conjugated with PEG-PLA. Polym Adv Technol. 2009;20(11):843-8.
11. Bae KH, Lee Y, Park TG. Oil-encapsulating PEO-PPO-PEO/PEG shell cross-linked nanocapsules for target-specific delivery of paclitaxel. Biomacromolecules. 2007;8(2):650-6. (Pubitemid 46323286)
12. O'Reilly RK, Hawker CJ, Wooley KL. Cross-linked block copolymer micelles: functional nanostructures of great potential and versatility. Chem Soc Rev. 2006;35(11):1068-83. (Pubitemid 44611720)
13. Shuai XT, Merdan T, Schaper AK, Xi F, Kissel T. Core-crosslinked polymeric micelles as paclitaxel carriers. Bioconjug Chem. 2004;15(3):441-8. (Pubitemid 38657848)
14. Xu YM, Meng FH, Cheng R, Zhong ZY. Reduction-sensitive reversibly crosslinked biodegradable micelles for triggered release of doxorubicin. Macromol Biosci. 2009;9(12):1254-61.
15. Tian L, Yam L, Wang JZ, Tat H, Uhrich KE. Core crosslinkable polymeric micelles from PEG-lipid amphiphiles as drug carriers. J Mater Chem. 2004;14(14):2317-24.
16. Kiss LE, Kovesdi I, Rabai J. An improved design of fluorophilic molecules: prediction of the ln P fluorous partition coefficient, fluorophilicity, using 3D QSAR descriptors and neural networks. J Fluor Chem. 2001;108(1):95-109. (Pubitemid 33618181)
17. Riess JG. Highly fluorinated amphiphilic molecules and self-assemblies with biomedical potential. Curr Opin Colloid Interface Sci. 2009;14(5):294-304.
18. Wolfson MR, Greenspan JS, Shaffer TH. Pulmonary administration of vasoactive substances by perfluorochemical ventilation. Pediatrics. 1996;97(4):449-55. (Pubitemid 26098290)
19. Kent KM, Cleman MW, Cowley MJ, Forman MB, Jaffe CC, Kaplan M, et al. Reduction of myocardial-ischemia during percutaneous transluminal coronary angioplasty with oxygenated fluosol. Am J Cardiol. 1990;66(3):279-84. (Pubitemid 20235750)
20. Spahn DR, van Brempt R, Theilmeier G, Reibold JP, Welte M, Heinzerling H, et al. European perflubron emulsion study, G., Perflubron emulsion delays blood transfusions in orthopedic surgery. Anesthesiology. 1999;91(5):1195-208. (Pubitemid 29506080)
21. Krafft MP. Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research. Adv Drug Deliv Rev. 2001;47 (2-3):209-28. (Pubitemid 32324115)
22. Janjic JM, Ahrens ET. Fluorine-containing nanoemulsions for MRI cell tracking. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(5):492-501.
23. Shao K, Huang RQ, Li JF, Han LA, Ye LY, Lou JN, et al. Angiopep-2 modified PE-PEG based polymeric micelles for Amphotericin B delivery targeted to the brain. J Control Release. 2010;147(1):118-26.
24. Vakil R, Knilans K, Andes D, Kwon GS. Combination antifungal therapy involving Amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles. Pharm Res. 2008;25(9):2056-64.
25. Vakil R, Kwon GS. Effect of cholesterol on the release of Amphotericin B from PEG-Phospholilpid micelles. Mol Pharm. 2008;5(1):98-104. (Pubitemid 351300039)
26. Gallis HA, Drew RH, Pickard WW. Amphotericin-B - 30 years of clinical-experience. Rev Infect Dis. 1990;12(2):308-29.
27. Girois SB, Chapuis F, Decullier E, Revol BGP. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2005;24(2):119-30. (Pubitemid 40487380)
28. Barwicz J, Tancrede P. The effect of aggregation state of amphotericin-B on its interactions with cholesterol- or ergosterol-containing phosphatidylcholine monolayers. Chem Phys Lipids. 1997;85(2):145-55. (Pubitemid 27129792)
29. Brajtburg J, Bolard J. Carrier effects on biological activity of Amphotericin B. Clin Microbiol Rev. 1996;9(4):512-31. (Pubitemid 26366536)
30. Bolard J, Legrand P, Heitz F, Cybulska B. One-sided action of amphotericin-B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry. 1991;30(23):5707-15.
31. Gruda I, Dussault N. Effect of the aggregation state of Amphotericin-B on its interaction with ergosterol. Biochem Cell Biol-Biochimie Biol Cell. 1988;66(3):177-83.
32. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, et al. Comparative efficacy and distribution of lipid formulations of Amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182(1):274-82. (Pubitemid 30497814)
33. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of Amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis. 2003;36(8):943-51. (Pubitemid 36513276)
34. Eriksson U, Seifert B, Schaffner A. Comparison of effects of Amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br Med J. 2001;322(7286):579-82. (Pubitemid 32234532)
35. Peleg AY, Woods ML. Continuous and 4 h infusion of Amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother. 2004;54(4):803-8. (Pubitemid 39386735)
36. Hiemenz JW. Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference? Clin Infect Dis. 2003;36(8):952-3. (Pubitemid 36513277)
37. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DRJ, et al. Mortality and costs of acute renal failure associated with Amphotericin B therapy. Clin Infect Dis. 2001;32(5):686-93. (Pubitemid 32221925)
38. Abla M, Durand G, Pucci B. Glucose-based surfactants with hydrogenated, fluorinated, or hemifluorinated tails: synthesis and comparative physical-chemical characterization. J Org Chem. 2008;73(21):8142-53.
39. Lavasanifar A, Samuel J, Kwon GS. The effect of alkyl core structure on micellar properties of poly(ethylene oxide)-block-poly (L-aspartamide) derivatives. Colloids Surf B Biointerfaces. 2001;22(2):115-26. (Pubitemid 32651677)
40. Winnik FM. Photophysics of preassociated pyrenes in aqueous polymer-solutions and in other organized media. Chem Rev. 1993;93(2):587-614.
41. Vakil R, Kwon GS. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) and PEG-phospholipid form stable mixed micelles in aqueous media. Langmuir. 2006;22(23):9723-9. (Pubitemid 44826387)
42. Kim SY, Shin ILG, Lee YM, Cho CS, Sung YK. Methoxy poly (ethylene glycol) and epsilon-caprolactone amphiphilic block copolymeric micelle containing indomethacin. II. Micelle formation and drug release behaviours. J Control Release. 1998;51(1):13-22. (Pubitemid 28064641)
43. Francis MF, Lavoie L, Winnik FM, Leroux JC. Solubilization of cyclosporin A in dextran-g-polyethyleneglycolalkyl ether polymeric micelles. Eur J Pharm Biopharm. 2003;56(3):337-46. (Pubitemid 37346506)
44. Jeong YI, Cheon JB, Kim SH, Nah JW, Lee YM, Sung YK, et al. Clonazepam release from core-shell type nanoparticles in vitro. J Control Release. 1998;51(2-3):169-78.
45. Riess JG. Fluorous micro- and nanophases with a biomedical perspective. Tetrahedron. 2002;58(20):4113-31. (Pubitemid 34467039)
46. Sadtler VM, Giulieri F, Krafft MP, Riess JG. Micellization and adsorption of fluorinated amphiphiles: questioning the 1CF(2)approximate to 1.5CH(2) rule. Chemistry-a European Journal. 10;4:1952-6.
47. Kissa E. Fluorinated surfactants: synthesis, properties, applications, vol. 50. New York: M. Dekker; 1994.
48. Graciani MD, Rodriguez A, Munoz M, Moya ML. Micellar solutions of sulfobetaine Surfactants in water-ethylene glycol mixtures: surface tension, fluorescence, spectroscopic, conductometric, and kinetic studies. Langmuir. 2005;21(16):7161-9. (Pubitemid 41156727)
49. Diezi TA, Bae Y, Kwon GS. Enhanced stability of PEG-block-poly(N-hexyl stearate L-aspartamide) Micelles in the Presence of Serum Proteins. Mol Pharm. 2010;7(4):1355-60.
50. Vakil R, Kwon GS. PEG-phospholipid micelles for the delivery of Amphotericin B. J Control Release. 2005;101(1-3):386-9.
51. Mukerjee P. Fluorocarbon hydrocarbon interactions in micelles and other lipid assemblies, at interfaces, and in solutions. Colloid Surface Physicochem Eng Aspect). 1994;84(1):1-10.
52. Soo PL, Luo LB, Maysinger D, Eisenberg A. Incorporation and release of hydrophobic probes in biocompatible polycaprolactoneblock-poly(ethylene oxide) micelles: implications for drug delivery. Langmuir. 2002;18(25):9996-10004.
53. Shuai XT, Ai H, Nasongkla N, Kim S, Gao JM. Micellar carriers based on block copolymers of poly(e-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J Contr Release. 2004;98(3):415-26. (Pubitemid 39093952)
54. Forrest ML, Won CY, Malick AW, Kwon GS. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly (epsilon-caprolactone) micelles. J Contr Release. 2006;110(2):370-7. (Pubitemid 41827491)
55. Lasic DD, Martin FJ. Stealth liposomes. Boca Raton: CRC; 1995.
56. Torchilin VP, Shtilman MI, Trubetskoy VS, Whiteman K, Milstein AM. Amphiphilic vinyl-polymers effectively prolong liposome circulation time in-vivo. Biochim Biophys Acta-Biomembr. 1994;1195(1):181-4. (Pubitemid 24318108)
57. Lukyanov AN, Gao ZG, Mazzola L, Torchilin VP. Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res. 2002;19(10):1424-9. (Pubitemid 35266545)
58. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419-36. (Pubitemid 36649037)
59. Maruyama K, Yuda T, Okamoto A, Ishikura C, Kojima S, Iwatsuru M. Effect of molecular-weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. Chem Pharm Bull. 1991;39(6):1620-2.
60. Liu F, Liu D. Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm Res. 1995;12(7):1060-4.